Resistant Starch
Potato-Based Supplement for Bone Marrow Transplant Patients
Recruiting0 awardsPhase 2
Ann Arbor, Michigan
This trial is testing a potato-based resistant starch supplement for patients receiving stem cell transplants. The goal is to see if this supplement can safely and effectively reduce a common complication called acute GVHD by boosting a helpful substance in the gut.
Alkylating agents
Bendamustine +/- Cyclophosphamide to Prevent GVHD Post Stem Cell Transplant for Blood Cancers
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing bendamustine, with or without cyclophosphamide, to see if it can help prevent GVHD in patients undergoing stem cell transplant.
Behavioral Intervention
Expressive Writing for Graft-versus-Host Disease
Recruiting1 awardPhase < 1
Chicago, Illinois
This trial investigates a new non-drug therapy for GVHD, a disease where donor cells attack the host body, to improve quality of life. The therapy, called expressive writing, involves writing and talking with others in a support group.
Mesenchymal Stem Cells
CYP-001 + Corticosteroids for Graft-versus-Host Disease
Recruiting0 awardsPhase 2
Evanston, Illinois
This trial studies how well a therapy, CYP-001, plus corticosteroids can help treat graft-versus-host disease (GvHD) after stem cell transplant. Subjects will receive either the therapy or a placebo, and GvHD severity will be assessed.
Popular Filters
Trials for Graft-versus-Host Disease Patients
Behavioral Intervention
Multidisciplinary Care for Graft-versus-Host Disease
Recruiting1 award
Boston, Massachusetts
This trial is testing whether a new, multidisciplinary approach to care can improve quality of life, symptoms, and psychological distress for people who have developed GVHD after a stem cell transplant.
Trials for Acute Lymphoblastic Leukemia Patients
Alkylating agents
GVHD Prophylaxis Regimens for Blood Cancer Stem Cell Transplant
Recruiting1 awardPhase 2
Seattle, Washington
This trial is studying two different drug combinations to reduce the risk of a common but serious complication called "graft versus host disease" (GVHD) following a blood stem cell transplant from an unrelated donor to treat blood cancer.
Immunotherapy
PTCy + Sirolimus/VIC-1911 for Acute Leukemia Post-transplant Care
Recruiting1 awardPhase 1 & 2
Minneapolis, Minnesota
This trial tests a combination of drugs to prevent complications after a stem cell transplant. It focuses on patients at risk of serious issues like GVHD and relapse. The drugs work together to protect the transplanted cells by suppressing the immune system. Cyclophosphamide combined with tacrolimus has been used to prevent GVHD after a stem cell transplant.
Monoclonal Antibodies
Tocilizumab for Blood Cancer Post-Transplant Care
Recruiting3 awardsPhase 2
New York, New York
This trial is testing whether ATG can be replaced with tocilizumab in the haplo-cord transplant conditioning regimen to improve immune reconstitution and reduce relapse while preserving low rates of graft failure and graft versus host disease.
Trials With No Placebo
Alkylating agents
Stem Cell Transplant for Severe Aplastic Anemia
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is for people with severe aplastic anemia, myelodysplastic syndrome, or paroxysmal nocturnal hemoglobinuria who want to receive a stem cell transplant using peripheral blood stem cells from a family member.
Immunosuppressant
High Dose Thymoglobulin for Graft-versus-Host Disease Prophylaxis
Recruiting3 awardsPhase 2
Calgary, Alberta
This trial will compare two different doses of ATG (a medication used to prepare the body for a stem cell transplant) to see which is more effective in preventing transplant complications.
Alkylating agents
GVHD Prophylaxis Regimens for Blood Cancer Stem Cell Transplant
Recruiting1 awardPhase 2
Seattle, Washington
This trial is studying two different drug combinations to reduce the risk of a common but serious complication called "graft versus host disease" (GVHD) following a blood stem cell transplant from an unrelated donor to treat blood cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.